Arrowhead to present on ARC-AAT at The Liver Meeting

Arrow Pharmaceuticals intends to give two presentations at The Liver Meeting 2016 on its investigational medicine designed to treat liver disease linked to alpha-1 antitrypsin deficiency, ARC-AAT.
“At The Liver Meeting, we will present initial results from Part A of a Phase 1 study indicating that ARC-AAT is well-tolerated and induces deep, durable, and dose-dependent knockdown of circulating alpha-1 antitrypsin. In addition, we will present mouse model data showing that over time ARC-AAT had the desired effect of preventing liver production of mutant Z-alpha1 antitrypsin polymers and reversing liver disease,” Arrowhead Chief Operations Officer and Head of Research and Development Bruce Given said. “The clinical abstract shows that ARC-AAT achieved reductions in serum AAT of up to 90 percent. Our previously reported primate studies indicate that approximately 10 percent of AAT may be produced outside the liver, so the Phase 1 clinical results suggest that we achieved near complete suppression of the liver produced AAT. This was an exciting result that gives us confidence as we conduct our ongoing Phase 2 multiple-dose study, which includes biopsies that will allow us to assess ARC-AAT’s histological effects.”
Set for Nov. 15-16 in Boston, the Liver Meeting is held annually by the AASLD.